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SHORT COMMUNICATION Open Access
Group-sequential analysis may allow for
early trial termination: illustration by an
intra-observer repeatability study
Oke Gerke1,2* , Mie H. Vilstrup1, Ulrich Halekoh3, Malene Grubbe Hildebrandt1,4
and Poul Flemming Høilund-Carlsen1,4
Abstract
Background: Group-sequential testing is widely used in pivotal therapeutic, but rarely in diagnostic research,
although it may save studies, time, and costs. The purpose of this paper was to demonstrate a group-sequential
analysis strategy in an intra-observer study on quantitative FDG-PET/CT measurements, illuminating the possibility
of early trial termination which implicates significant potential time and resource savings.
Methods: Primary lesion maximum standardised uptake value (SUVmax) was determined twice from preoperative
FDG-PET/CTs in 45 ovarian cancer patients. Differences in SUVmax were assumed to be normally distributed, and
sequential one-sided hypothesis tests on the population standard deviation of the differences against a hypothesised
value of 1.5 were performed, employing an alpha spending function. The fixed-sample analysis (N = 45) was compared
with the group-sequential analysis strategies comprising one (at N = 23), two (at N = 15, 30), or three interim analyses
(at N = 11, 23, 34), respectively, which were defined post hoc.
Results: When performing interim analyses with one third and two thirds of patients, sufficient agreement could be
concluded after the first interim analysis and the final analysis. Other partitions did not suggest early stopping after
adjustment for multiple testing due to one influential outlier and our small sample size.
Conclusions: Group-sequential testing may enable early stopping of a trial, allowing for potential time and resource
savings. The testing strategy must, though, be defined at the planning stage, and sample sizes must be reasonably
large at interim analysis to ensure robustness against single outliers. Group-sequential testing may have a place in
accuracy and agreement studies.
Keywords: Agreement, Bland-Altman plot, Repeatability, Reproducibility, Sample size
Background
Planning, conduct, analysis, and report of clinical trials
require comprehensive resources. Most clinical trials
employ fixed-sample designs in which the data of all pa-
tients are collected and first examined at the end of the
study. In contrast, group-sequential trial designs are
hallmarked by predefinition of number, time points, and
stopping rules of interim analyses to enable the trial to
be terminated early due to either fertility or futility
should the trial develop against former expectations.
This built-in possibility requires adjustment of analyses
for multiple testing, for which suitable approaches are at
hand [1, 2]. While group-sequential testing is regularly
done in pivotal clinical trials with therapeutic intent, it is
much less common in diagnostic trials. The purpose of
this paper was to demonstrate a group-sequential ana-
lysis strategy in an intra-observer study on quantitative
FDG-PET/CT measurements, illuminating the possibility
of early trial termination which implicates significant
potential time and resource savings.* Correspondence: oke.gerke@rsyd.dk
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Methods
Bland-Altman limits of agreement
The agreement of paired, quantitative measurements in
method comparison or observer variation studies is
often assessed with Bland-Altman plots with respective
limits of agreement [3, 4]. These limits consist of the
mean difference of the paired measurements ± 1.96
times the sample standard deviation of these differences
[5–7]. Implicitly, it is assumed that the paired differences
of the whole target population from which the sample
was taken follow a normal distribution; then, the Bland-
Altman limits of agreement comprise, on average, 95%
of all observations according to the 68-95-99.7 rule [8]
and can be interpreted as prediction interval.
In the following, we will base the statistical analysis
strategy on the true (but unknown) population standard
deviation of the paired differences. By this means, the
Bland-Altman limits of agreement and the applied statis-
tical hypothesis test are by definition interrelated.
Primary hypothesis
We are interested in testing that the true (but unknown)
population standard deviation of the paired differences is
smaller than a benchmark below which agreement would
be assessed to be acceptable from a clinical point of view.
Therefore, our primary hypothesis reads: The observed
sample standard deviation falls sufficiently small of a
predefined benchmark, implicating that the true (but
unknown) population standard deviation is likely to be
smaller than that benchmark as well. Or, in more technical
terms: we will test statistically whether the sample stand-
ard deviation is significantly smaller than the benchmark.
Statistical test
The respective statistical hypothesis test to answer the
primary hypothesis above is a one-sided hypothesis test
on the population standard deviation of the paired dif-
ferences between measurements (σ) against a predefined
benchmark (σ0):
Null hypothesis (H0): σ ≥ σ0 vs. alternative hypothesis
(Ha): σ < σ0.
Assuming that the paired differences follow a normal
distribution, the test statistic
χ2 ¼ n−1ð Þs
2
σo2
follows a chi-square distribution with n − 1 degrees of
freedom, where n denotes the number of paired mea-
surements and s the sample standard deviation [8, 9].
Corresponding upper one-sided confidence limits are
constructed by using the very same test statistic and
were supplemented.
Below, we will work with the benchmark σ0 = 1.5 for
exemplification purposes.
Group-sequential testing with an α-spending function
The spending function approach specifies a sequential de-
sign directly in terms of αt, the significance levels for in-
terim and final analyses which depend on the amount of
hitherto accumulated information in terms of observations
gathered. The basic idea is to use significance levels
smaller than the nominal significance level (of usually 5%)
in interim analyses in order to secure that the probability
of falsely rejecting the null hypothesis at any interim ana-
lysis or at the final analysis does not exceed the nominal
significance level. We set this nominal experiment-wise
level of significance, α, to 5% and employed the α-
spending function αt = αt [10], where t and αt denote the
proportion of accumulated information and the signifi-
cance level to which the realised P value is to be compared
with at a particular analysis time point, respectively. Here,
we defined post hoc three different group-sequential ana-
lysis strategies comprising one (at N = 23), two (at N = 15,
30), or three interim analyses (at N = 11, 23, 34), respect-
ively. These led to significance levels for the interim ana-
lyses of α0.5 = 0.05 × 1/2 = 0.025; α0.33 = 0.05 × 1/3 = 0.0167
and α0.67 = 0.05 × 2/3 = 0.0333; and α0.25 = 0.05 × 1/4 =
0.0125, α0.5 = 0.05 × 1/2 = 0.025, and α0.75 = 0.05 × 3/4 =
0.0375, respectively. Final analysis was done with 45 pa-
tients and a significance level α1 = 0.05.
Clinical example
We used data from an ongoing clinical study in patients
with suspicion of ovarian cancer which was described
elsewhere [11]. In brief, this study’s primary hypothesis
was that dual time FDG-PET/CT performed at 60 and
180 min after injection of tracer would increase the diag-
nostic accuracy of FDG-PET/CT imaging (routinely per-
formed at 60 min only) for preoperative assessment of
resectability, provided optimal debulking is achievable.
Data from 45 patients scanned between 7 Aug 2013 and
7 Jun 2016 were used. The assessment of the FDG-PET/
CT scans performed at 60 min was done twice in a
blinded fashion with 2 months in between by author
MHV in order to investigate the intra-observer repeat-
ability at post imaging processing. The primary ovarian
cancer lesion maximum standardised uptake value
(SUVmax (g/ml)) was determined when the lesion was
identifiable; otherwise, the SUVmax in peritoneal carci-
nosis was used.
Software implementation and source code
All analyses were performed by using Stata/MP 14.2
(StataCorp LP, College Station, Texas 77845, USA). The
dataset and the Stata source code are accessible as
Additional file 1 and Additional file 2, respectively.
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Results
The differences between the two repeated SUVmax read-
ings at 60 min were all less than one in absolute terms,
apart from those of patient no. 3, 5, 10, 23, 26, and 42
(Fig. 1). The by far largest difference between the two
measurements was observed for patient no. 23 (6 g/ml).
Bland-Altman limits of agreement
At the final analysis (N = 45), the estimated mean differ-
ence between the paired measurements and the Bland-
Altman limits of agreement were 0.30 and − 1.78 to 2.38.
Only when patient no. 23 was not part of the first in-
terim analysis was the estimated mean difference smaller
and Bland-Altman bands narrower than those at the
final analysis (with two interim analyses 0.25, − 1.53 to
2.03 (N = 15); with three interim analyses 0.19, − 1.85 to
2.24 (N = 11); see Table 1). The estimated mean differ-
ences and the Bland-Altman limits of agreement are
shown for the analysis strategy comprising two interim
analyses (Fig. 2).
Fixed-sample analysis (N = 45)
Without any interim analysis, no adjustment for mul-
tiple testing was necessary and the study was analysed
after collection of all data. The observed standard devi-
ation of 1.060 was statistically significantly smaller than
that of the benchmark σ0 = 1.5 (P = 0.0022), and the
upper confidence limit (uCL) was 1.288, meaning
accordingly smaller than 1.5 (Table 2).
Sequential testing
Employing one, two, or three interim analyses before the
final analysis, statistical testing at all interim analysis
time points was adjusted for multiple testing in each
strategy by adjusting significance levels as described
above. Only the analysis strategy using two interim
analyses suggested already sufficient agreement of the
repeated readings by rejection of the null hypothesis at
the first interim analysis (N = 15); the observed standard
deviation of 0.909 was statistically significantly smaller
than 1.5 (P = 0.0162 < α0.33 = 0.0167), and the uCL was,
similarly, 1.495 < 1.5 (Table 2).
Neither incorporation of only one nor implementation
of three interim analyses led to early stopping due to suffi-
cient agreement. The influence of one outlier (patient no.
23 in whom the two measurements differed by 6 g/ml)
was clearly visible as SD = 1.415 with N = 23 exceeded
SD = 1.060 at the end of the study (N = 45).
Discussion
Statement of principal findings
While diagnostic studies in general and agreement studies
in particular usually make use of fixed-sample designs, we
applied a post hoc group-sequential design for a one-sided
hypothesis test setting on the variability of the paired dif-
ferences in an intra-observer study and exemplified that
the conclusions were the same for the first interim ana-
lysis (N = 15) and the final analysis (N = 45) when con-
ducting interim analyses with one third and two thirds of
all patients. On the contrary, no interim analysis suggested
early stopping when interim analyses were performed with
one half or one fourth, one half, and three fourths of all
patients due to one influential outlier and our comparably
small sample size.
Strengths and weaknesses of the study
The α-spending function used here [10] is simple and
straightforward to apply, and interim analyses open up
the opportunity to stop early in case of an early indica-
tion of sufficient agreement. Under the assumption of
normally distributed differences, the statistical test pro-
cedure follows standard theory and has a natural link to
the commonly used Bland-Altman limits of agreement.
With small sample sizes as ours, both the testing pro-
cedure and the Bland-Altman limits of agreement are
sensitive to outliers. Here, the SUVmax assessments for
patient no. 23 differed by 6 g/ml. Excluding this patient
from the second interim and the final analysis in the
analysis strategy comprising two interim analyses led to
smaller values for the standard deviation (0.696 and
0.614, respectively) and the upper one-sided 96.67% and
95% confidence limits of σ (0.922 and 0.748, respect-
ively), mean differences decreased (0.24 and 0.17,
respectively), and Bland-Altman limits of agreement
turned narrower (− 1.13 to 1.60 and − 1.03 to 1.37,
respectively; data not shown). In general, sample sizes of
at least 30 observations are recommended when apply-
ing the central limit theorem to the sampling distribu-
tion of a mean [8]; when dealing with a variance
parameter as target, probably 50 should be the minimum
number of paired observations since estimating second
Fig. 1 Scatterplot of repeated SUVmax measurements of 60-min
scans for 45 patients (blue: 1st reading, red: 2nd reading)
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moments (like the variance) is more prone to uncer-
tainty than estimating first moments (like the mean).
In order to ensure robustness against single outliers,
also interim analyses should comprise ‘sufficiently many’
observations. However, once the analysis strategy is fixed
and the time points for interim analyses specified, the
investigator needs to stick to the schedule, eventually
happily ending with an earlier termination of the study
(as in case of our interim analysis with one third of all
patients) or having to continue after an early interim
analysis due to one outlier (see our alternative partition
with the first interim analysis with one half of all
patients).
A fundamental challenge in planning an agreement
study as the one shown here is the a priori fixation of the
hypothesised value for the population standard deviation,
σ0. Moreover, we focused on one simple α-spending func-
tion while other less easily accessible α-spending functions
gained broader applicability [12, 13]. Finally, we fixed the
maximum number of observations of the study and did
not consider an adaptive design in which the sample size
may be adjusted after the first interim analysis if the ori-
ginal assumptions for the sample size calculations do not
hold [14–16].
Meaning of the study: possible mechanisms and
implications for clinicians and policymakers
Agreement studies can either be conducted as such or
as part of larger diagnostic accuracy studies for which
the assessment of agreement serves quality control pur-
poses; then, usually, just a few sentences are dedicated
to agreement results due to limited space for reporting
Table 1 Estimated mean difference and Bland-Altman limits of agreement for the paired differences of measurements
Number of
interim
analyses
Estimated mean difference and Bland-Altman limits of agreement at analysis time point
Interim analysis 1 Interim analysis 2 Interim analysis 3 Final analysis
0 – – – 0.30
–1.78 to 2.38 (N = 45)
1 0.47
–2.30 to 3.24 (N = 23)
– – 0.30
–1.78 to 2.38 (N = 45)
2 0.25
–1.53 to 2.03 (N = 15)
0.43
–2.03 to 2.89 (N = 30)
– 0.30
–1.78 to 2.38 (N = 45)
3 0.19
–1.85 to 2.24 (N = 11)
0.47
–2.30 to 3.24 (N = 23)
0.40
–1.92 to 2.73 (N = 34)
0.30
–1.78 to 2.38 (N = 45)
Fig. 2 Bland-Altman plots: upper, middle, and lower panel plots comprise N = 15, 30, and 45 patients, respectively
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[3]. The employment of group-sequential designs in
agreement studies enables early termination when suffi-
cient agreement has been achieved according to an in-
terim analysis. In this way, the image reading extent can
be optimised, and resources can be spent more effi-
ciently. The application of group-sequential design
methodology in agreement studies should be considered
when planning agreement studies in the future.
Group-sequential designs can likewise be easily imple-
mented in other settings than agreement studies. We in-
vestigated the diagnostic accuracy of FDG-PET/CT with
dual time point imaging (60 and 180 min), contrast-
enhanced CT, and bone scintigraphy in patients with
suspected breast cancer recurrence previously in a pro-
spective study [17]. Testing the global hypothesis on
equality of the areas under the ROC curves was per-
formed once at the end of the study (N = 100) but could
as well have served as primary hypothesis for interim
analyses with, for instance, one half or one third and two
third of the sample size. Implementing post hoc group-
sequential analysis strategies in the same way as above,
i.e. comprising one (at N = 50), two (at N = 33, 67), or
three interim analyses (at N = 25, 50, 75), did not lead to
early termination of the study at any interim analysis
(Table 3). This emphasises the fact that an analysis strat-
egy employing interim analyses may or may not lead to
early termination of the study: depending on the effect
size and its variability, it may turn out that the originally
planned total sample size is still required for demonstra-
tion of a statistically significant difference between
different regimes.
Unanswered questions and future research
How can early stopping rules for both fertility and fu-
tility be established in group-sequential agreement
studies? Can continuous designs without a priori-
specified analysis time points (e.g. triangular test [1])
be adapted to an agreement setting? How can a non-
parametric test targeting the spread of data be con-
structed when the assumption of normally distributed
differences does not hold? Can an interrelation be
established between such a test and nonparametric
Bland-Altman limits of agreement?
Table 2 Sequential testing on population standard deviation σ
Number of
interim analyses
Observed standard deviation, P value (sample size), respective significance level, and upper confidence limit at analysis time point
Interim analysis 1 Interim analysis 2 Interim analysis 3 Final analysis
0 – – – SD = 1.060
P = 0.0022 (N = 45)
α1 = 0.05
95% uCL 1.288
1 SD = 1.415
P = 0.3900 (N = 23)
α0.5 = 0.025
97.5% uCL 2.002
– – SD = 1.060
P = 0.0022 (N = 45)
α1 = 0.05
95% uCL 1.288
2 SD = 0.909
P = 0.0162 (N = 15)
α0.33 = 0.0167
98.33% uCL 1.495
SD = 1.255
P = 0.1162 (N = 30)
α0.67 = 0.0333
96.67% uCL 1.653
– SD = 1.060
P = 0.0022 (N = 45)
α1 = 0.05
95% uCL 1.288
3 SD = 1.044
P = 0.0984 (N = 11)
α0.25 = 0.0125
98.75% uCL 2.006
SD = 1.415
P = 0.3900 (N = 23)
α0.5 = 0.025
97.5% uCL 2.002
SD = 1.185
P = 0.0452 (N = 34)
α0.75 = 0.0375
96.25% uCL 1.519
SD = 1.060
P = 0.0022 (N = 45)
α1 = 0.05
95% uCL 1.288
SD standard deviation, uCL upper confidence limit, italics rejection of null hypothesis
Table 3 Sequential testing on equality of areas under ROC curves [17]
Number of
interim
analyses
P value (sample size) and respective significance level at analysis time point
Interim analysis 1 Interim analysis 2 Interim analysis 3 Final analysis
0 – – – 0.0189 (N = 100) α1 = 0.05
1 0.1557 (N = 50) α0.5 = 0.025 – – 0.0189 (N = 100) α1 = 0.05
2 0.0669 (N = 33) α0.33 = 0.0167 0.0577 (N = 67) α0.67 = 0.0333 – 0.0189 (N = 100) α1 = 0.05
3 0.0174 (N = 25) α0.25 = 0.0125 0.1557 (N = 50) α0.5 = 0.025 0.0395 (N = 75) α0.75 = 0.0375 0.0189 (N = 100) α1 = 0.05
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Conclusions
Group-sequential testing in agreement studies offers
the possibility of early termination of the trial, imply-
ing potential time and resource savings, but timing of
and decision rules for interim analyses must be a priori
specified in the study protocol in order to secure the
experiment-wise type I error probability. Sample sizes
must be reasonably large at the time point of interim
analysis to ensure robustness against single outliers.
Our example was retrospectively analysed, and its re-
sults were, indeed, sensitive to one outlier. Group-
sequential testing that is widely used in pivotal thera-
peutic studies of drug development can also be of con-
siderable value in accuracy and agreement studies.
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